However, to date, no study has incorporated analysis of clinical outcome with a detailed characterisation of TP53 alterations in paediatric B-NHL where BL predominates, and the potential utility of TP53 status as a clinical risk stratifier in this age group has remained unclear. Here, TP53 is linked to Burkitt lymphoma.